Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Covidien's Sleep Diagnostic business acquired by Embla

Embla and Covidien have entered into a definitive agreement under which Embla will acquire Covidien's Sleep Diagnostic business. This includes the sleep diagnostic products sold under the Sandman(TM) brand name. Financial terms of the transaction were not disclosed. Completion of the sale is subject to customary closing conditions.

4 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

Daxor's signed trial agreement with Pacific Cardiology to provide the BVA-100 instrument

Daxor Corporation, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Pacific Cardiology, LLC of Honolulu, Hawaii. This will provide Pacific Cardiology with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume.

1 Sep 2009

NYP/Weill Cornell research reveals that prolonged QRS duration indicates abnormal pumping of the heart

QRS duration (QRSd) is one of several measures of heart function recorded during a routine electrocardiogram (ECG). It is a composite of waves showing the length of time it takes for an electrical signal to get all the way through the pumping chambers of the heart. Prolonged QRSd is a sign of an abnormal electrical system of the heart and is often found when the heart isn't pumping efficiently.

28 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

The Society of Chest Pain Centers announces a new grant program to encourage clinical research

The Society of Chest Pain Centers (www.SCPCP.org), an international non-profit organization focused on improving care for cardiac patients, announces a new grant program in an effort to support research that is likely to result in a substantive contribution to acute cardiovascular medicine.

26 Aug 2009

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a study in the August 26 issue of JAMA.

26 Aug 2009

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

24 Aug 2009

HeartWare achieves enrollment milestone under its ADVANCE Clinical Trial in the U.S

HeartWare International, Inc. (Nasdaq: HTWR - ASX: HIN) today announced that HeartWare has surpassed 50 implants in the United States under its ADVANCE Clinical Trial, marking an important early enrollment milestone.

21 Aug 2009

Medicare picks twelve New Jersey hospitals to test incentive system

Twelve New Jersey hospitals and their participating physicians have received approval from the federal government to test an innovative new incentive method that aims to reduce healthcare costs while improving quality of care.

19 Aug 2009

Texas Heart Institute receives $4.1 million to determine the effect of pulseless blood flow on bodily functions

The National Institutes of Health (NIH) has awarded a $4.1 million grant to the Texas Heart Institute at St. Luke’s Episcopal Hospital (THI at SLEH) to determine the effect of pulseless blood flow on bodily functions. This knowledge will be used in the development of a total artificial heart (TAH) that produces continuous, pulseless blood flow.

18 Aug 2009

Response Biomedical announces Q2 2009 financials

Response Biomedical Corporation (TSX:RBM) (OTCBB:RPBIF) reported that clinical products revenue for the three and six month periods ended June 30, 2009 increased 373% and 208% to $1,805,308 and $3,548,014, respectively, compared to $381,615 and $1,150,760 for the same periods in 2008.

13 Aug 2009

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Sanofi-aventis Canada announced today that Multaq (dronedarone, 400 mg tablets) has received Health Canada approval for the treatment of patients with a history of, or current atrial fibrillation to reduce their risk of cardiovascular hospitalization due to this condition.

12 Aug 2009

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.

11 Aug 2009

Health-related quality of life in chronic kidney disease patients

Chronic kidney disease (CKD) can significantly lessen patients' quality of life, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Certain types of patients - women, diabetics, and those with a history of heart complications - are most affected.

31 Jul 2009

Costliest Medicare markets in Florida, New York, California

U.S. News & World Report examines cost, frequency, and outcomes studies on Medicare patients from the Dartmouth Institute for Health Policy and Clinical Practice : "The Dartmouth research is particularly relevant to older Americans because it is based to a large extent on Medicare data, involving patients ages 65 and older.

8 Jul 2009

Multaq approved for atrial fibrillation by FDA

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.

7 Jul 2009

New strategies to improve treatment and prevent heart failure in children

Structural cardiovascular abnormalities present at birth are the leading cause of heart failure in children. Nearly half a million children in the United States have structural heart problems ranging in severity from relatively simple issues, such as small holes between chambers of the heart, to very severe malformations, including complete absence of one or more chambers or valves.

7 Jul 2009

Lawmakers want Federal rules to cover home health care workers and end-of-life care

Lawmakers want federal rules to cover home health care workers while Sen. Mark Warner, D-Va., plans to introduce legislation in Congress today to better educate the public on end-of-life care.

13 Jun 2009

FDA approves injectable Ibuprofen

The U.S. Food and Drug Administration today approved Caldolor, the first injectable dosage form of the common pain medication ibuprofen, to treat pain and fever.

11 Jun 2009

Congestive Heart Failure News and Research

Covidien's Sleep Diagnostic business acquired by Embla

Cimzia approved for treating adult patients with rheumatoid arthritis

Daxor's signed trial agreement with Pacific Cardiology to provide the BVA-100 instrument

NYP/Weill Cornell research reveals that prolonged QRS duration indicates abnormal pumping of the heart

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

The Society of Chest Pain Centers announces a new grant program to encourage clinical research

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

HeartWare achieves enrollment milestone under its ADVANCE Clinical Trial in the U.S

Medicare picks twelve New Jersey hospitals to test incentive system

Texas Heart Institute receives $4.1 million to determine the effect of pulseless blood flow on bodily functions

Response Biomedical announces Q2 2009 financials

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Health-related quality of life in chronic kidney disease patients

Costliest Medicare markets in Florida, New York, California

Multaq approved for atrial fibrillation by FDA

New strategies to improve treatment and prevent heart failure in children

Lawmakers want Federal rules to cover home health care workers and end-of-life care

FDA approves injectable Ibuprofen

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News